Description
Copegus (Ribavirin USP) 200mg Online
Copegus (Ribavirin USP) is an antiviral medicine. It is used with other medicines to treat hepatitis C. Copegus is used in combination with injectable interferon alfa-2b, peginterferon alfa-2a, or peginterferon alfa-2b to treat chronic hepatitis C infection. The combination of Copegus and peginterferon alfa-2b is used to treat adults and children 3 years of age and older who show symptoms of liver damage. Copegus is an antiviral agent that treats the hepatitis C virus.
Copegus (Copegus) is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus. Treatment early in the course of severe lower respiratory tract infection may be necessary to achieve efficacy. Only severe RSV lower respiratory tract infection should be treated with Copegus (Copegus). The vast majority of infants and children with RSV infection have a disease that is mild, self-limited and does not require hospitalization or antiviral treatment. Many children with mild lower respiratory tract involvement will require shorter hospitalization than would be required for a full course of Copegus (Copegus) aerosol (3 to 7 days) and should not be treated with the drug. Thus the decision to treat with Copegus (Copegus) should be based on the severity of the RSV infection. The presence of an underlying condition such as prematurity, immunosuppression, or cardiopulmonary disease may increase the severity of clinical manifestations and complications of RSV infection. The use of aerosolized Copegus (Copegus) in patients requiring mechanical ventilator assistance should be undertaken only by physicians and support staff familiar with this mode of administration and the specific ventilator being used.
